RafflesMedicalGroup has announced a robust financial performance for the second half of 2025, with Profit After Tax and Minority Interests (PATMI) increasing by 22% to S$38.5m compared to the same period in 2024. The full-year PATMI for 2025 also saw a 13.4% rise, reaching S$70.6m, bolstered by strong performances in the Hospital Services and Insurance divisions, as well as gains from investment properties.
The Group’s revenue for the full year grew by 1.8% to S$765.3m, attributed to higher patient volumes, improved average bill sizes, and operational efficiencies. The Hospital Services Division alone reported a 3.5% increase in revenue, amounting to S$357.8m, with profits rising by 15.3% to S$41.1m. This growth was supported by steady patient volumes and operational efficiencies in both Singapore and China.
RafflesHealthinsurance recorded a 4.1% revenue growth, reaching S$185.2m in 2025, driven by contract repricing and new contracts. Despite a challenging insurance environment, profitability improved by 50.6% due to disciplined claims management and expense control.
The Group maintained a healthy cash position with S$310.8m in cash and equivalents as of 31 December 2025, allowing for strategic growth initiatives and shareholder returns. A final dividend of 3.0 cents per share has been proposed, representing 84% of sustainable Group PATMI.
Looking ahead, RafflesMedicalGroup plans to expand its services across Asia and adopt advanced technologies, including AI, to enhance healthcare delivery. The upcoming RafflesHealthyLongevityCentre, set to open in Q1 2026, will focus on personalised and preventive care, aiming to help individuals achieve healthier, longer lives. The Group remains optimistic about its profitability in FY2026, as it continues to adapt to demographic and regulatory changes in its operating regions.
